The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- BMS Seeks to Block Sawai’s Sprycel Generic over CML Use
November 7, 2023
- Xocova Claims 1st Trophy in August GP Promotion, Dayvigo Makes Comeback in HP List
November 6, 2023
- Kazunari Tsunaba Steps Down as CEO of Aculys Pharma
November 6, 2023
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Shionogi, Apnimed to Launch Joint Venture to Develop Sleep Apnea Drugs
November 2, 2023
- Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
- Mitsubishi Tanabe’s April-September Sales Up 8% on Radicava
November 2, 2023
- Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
November 2, 2023
- Otsuka Ups 2023 Full-Year Sales Forecast on Bullish Global Brands
November 2, 2023
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
- Daiichi Sankyo to Merge 2 Subsidiaries to Enhance ADC Production
November 1, 2023
- Otsuka Files Rexulti for Alzheimer’s Associated Agitation in Japan
November 1, 2023
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
- BIKEN Files Updated Version of Measles-Rubella Vaccine Mearubik
October 31, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…